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Platelet-derived growth factor: A key regulator of connective tissue cells
in embryogenesis and pathogenesis. Studies of PDGF-A, PDGF-B and
PDGF receptor-a knock-out mice have revealed critical functions for the
PDGF-PDGF receptor signaling systems in the ontogeny of connective
tissue cells: the mesangial cells of kidney glomeruli and the alveolar
smooth muscle cells (SMC) of the lung. The phenotypes of the PDGF
mutant mice have also shed light on the identity and functions of these cell
types, as well as revealed analogies suggesting that common morphoge-
netic principles have evolved for use in different organs, involving related
growth factors and cell types. Although the lethality of PDGF knock-out
mice has not allowed an investigation of the role of PDGF in SMC of the
vessel wall, regulation of PDGF and its receptors in adult vessels following
injury is consistent with a role for PDGF in the fibroproliferative response
in the intima that occurs as part of the pathogenesis of atherosclerosis.
PDGF modulation of connective tissue synthesis may thus be critical to
connective tissue phenotype and proliferation in both embryogenesis and
pathogenesis.
The PDGFs are dimers of A- and/or B-chains that bind to and
activate two related receptor tyrosirie kinases, PDGFRa and -/3
[1]. Receptor occupation by ligand leads to receptor dimerization
allowing for autophosphorylation and subsequent association of
receptor kinase substrates. PDGF is one of the best studied
growth factors from the point of view of receptor tyrosine
kinase-mediated signal transduction [2]. PDGF receptors are
particularly localized on connective tissue cells [3]. In vitro, a
selective list of PDGF actions on connective tissues cells includes:
migration; proliferation; contraction; inhibition of gap junctional
communication; and alteration of cellular metabolic activities
including matrix synthesis, cytokine production, and lipoprotein
uptake [4].
Because of its multiplicity of activies, much attention has been
also focused on the involvement of PDGF in the pathogenesis of
various diseases, ranging from atherosclerosis to rheumatoid
arthritis, liver cirrhosis and cancer [3]. Relatively little attention,
on the other hand, has been directed towards the normal physi-
ological functions of the PDGFs, including functions during
embryonic development. For the study of the latter, genetic
analysis using gene targeting approches may prove particularly
useful since there is a limited number of loci to target (2 ligand
and 2 receptor genes), and since the ligand-receptor cross speci-
ficity pattern has been relatively well established. To date, reports
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have been published on three out of the four possible knock-outs:
PDGF-B [5], PDGFRJ3 [6] and PDGF-A [7]. As expected, these
studies have revealed important information concerning the nor-
mal physiological functions of the PDGFs during mouse embry-
onic development.
Of equal importance have been the information derived from
PDGF knock-out studies concerning the existence and function of
specific populations of connective tissue cells. These findings may
also have implications for the role of PDGFs and of connective
tissue cells in the pathogenesis of various diseases. The aim of the
present review is to summarize the findings on PDGF knock-out
mice and to discuss them in the context of morphogenesis and
pathogenesis, with a particular focus on regulation of connective
tissue cells.
Strategies for genetic analysis of PDGF function
In the targeted disruption of gene function [8], a number of
different strategies may be chosen that all suffer from their
respective advantages and drawbacks. Large deletions including
the promoter region have the advantage that they provide com-
plete silencing of the gene of interest. Remaining expression of an
abnormal protein from the targeted allele could potentially have
adverse effects including dominant negative functions. The possi-
ble drawback of extensive changes to the gene's structure was
recently brought up by Olson et al [9] and illustrated in the
example of the MRF4 gene, in which case some but not all
mutations had silencing effects also on the neighboring myf5
locus. Such unpleasant surprises could probably be avoided in
most cases by introducing small mutations restricted to the coding
region of the target gene.
In the case of the mutagenesis of the PDGF genes, deletion of
the entire exon 4 in both genes was performed [5, 7]. Potential
exon skipping in the mutant allele leading to fusion of exon 3 and
5 encoded sequences in a resulting mRNA molecule would result
in a frame shift in the sequence corresponding to exons 5 to 7. The
resulting mutant alleles would not be able to produce PDGF since
the mature PDGF chains are encoded by exons 4 to 6 in both the
PDGF-A and -B genes.
Although the embryonic lethal phenotypes in the PDGF and
PDGF receptor-null mice have provided insights into the role of
PDGF iii development as detailed below, they do not allow the
testing of the contribution of PDGF to pathologic processes in
adult animals. Within developing lesions of atherosclerosis, the
primary source of PDGF appears to be macrophages [10, ii], and
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following acute injury of the vessel wall, platelets [12, 131. Thus,
the circulating cells represent the principle source of PDGF in
these pathologic responses. Therefore, chimeras in which the
infiltrating cells are replaced with PDGF null cells can be created
by lethal irradiation of a normal host mouse and repopulation of
the bone marow with fetal liver cells from PDGF —I— embryos.
As illustrated in Figure 1, if the irradiated host is the Apo E
deficient mouse that spontaneously develops lesions of atheroscle-
rosis like those seen in humans [14], the role of PDGF in
circulating cells in the development of these lesions can be
investigated. These experiments are currently in progress and
promise to test specific roles of PDGF in adult animals. Another
approach to analyze the function of PDGF in adults is generation
of fusion chimeras in which embryo stem cell lines are derived
from —/-- and +/+ blastocysts, injected into host blastocysts, and
grown to term in a surrogate mother [151. The —I— cells can be
distinguished from the wild-type host cells by markers and the
wild-type cells will carry the embryo to term. The absence of
derivatives of a particular cell type will be indicative of a require-
ment of the deleted gene for that lineage or response.
PDGF-B and PDGFR knock-out mouse phenotypes
The PDGF-B and -R13 null phenotypes are embryonic lethal
and strikingly similar [5, 6]. At late gestation (E17-19) homozy-
gous mutants develop general hemorrhaging and edema. At the
time of birth, many homozygotes still display life signs, such as
beating hearts and motorical reflexes. However, the homozygotes
do not start breathing regularly either following natural delivery
or subsequent to caesarean delivery at E18.5. Thus, the latest the
homozygous PDGFB mutants die is shortly after birth. To date,
several hundred offspring to heterozygous parents have been
genotyped without a single case observed of postnatal survival of
PDGF-B homozygotes.
The underlying cause of the bleedings in PDGF-B and -Rf3
knock-outs is currently under investigation. Thrombocytopenia
has been noticed in both mutants but is not likely to be the sole
cause of bleeding, since more severely thrombocytopenic mutant
mice either fail to display hemorrhaging, or show homorrhaging,
but at later time point in life than do the PDGF-B and -Rp
knock-outs [16, 171. Standard coagulation tests have been applied
to PDGF-B null blood, and failed to reveal a significant difference
to the wild-type blood (Lindahl et al, manuscript in preparation).
Attention is therefore focused on the developing blood vessel
wall. Preliminary data suggest the existence of a blood vessel
wall developmental defect in PDGF-B knock-outs. However,
this issue requires further study and the data will not be
reviewed here.
Both PDGF-B and -R/3 knock-out embryos display a develop-
mental defect of the kidney glomerulus that consists of a complete
lack of mesangial cells (Fig. 2). Probably as a result of the
mesangial cell deficiency, a capillary tuft is not formed. Rather, a
few, or a single, micro-aneurysm-like capillary loops fill out the
Bowman's space. Several features of the knock-out glomerulus
malformation provide information as to the normal function of
rnesangial cells. First, the lack of glomerular basement membrane
folding suggests that this morphogenic process is accounted for by
the mesangial cells. The mesangial cells are normally embedded in
a dense collagenous matrix refered to as the mesangial matrix.
This matrix is focally attached to the inner leaflet of the glomer-
ular basement membrane. It is likely that this focal attachment,
perhaps combined with mesangial cell contractility, provides the
critical structures and forces promoting glomerular basement
membrane (and podocyte) folding. Second, the lack of a capillary
network suggests either that mesangial cells promote capillary
branching or that branches, once formed, are inhibited from
fusing with each other by intervening mesangial cells. Thirdly, the
ultrastructure of the glomerulus lacking mesangial cells provides
an immediate suggestion for a function of the mesangial cells as
an inner mechanical support, or "filter holder," for the glomerular
basement membrane. In the PDGF-B and -R/3 knock-out glomer-
uli, the glomerular basement membrane with attached podocytes,
appear tightly squeezed towards the parietal Bowman's epithe-
hum (Fig. 3). Thus, filtration and the production of primary urine
should be severely compromised for mechanical reasons; the
collapse of the filter unit leads to reduced collection and drainage
of the filtrate. The suggestion for a critical filter holder function of
the mesangial cells finds support from studies showing reduced
urine collection in the urinary bladders of E18.5 PDGF-B null
embryos in comparison with wild-type and heterozygous litter-
mates [51. The comparison with hittermates is critical for timing
reasons since urine collection in the bladder is seen for the first
time at E18.5 as a swelling of the urinary bladder. Whereas the
control urinary bladders had acquired a round shape and clearly
contained urine, no visible signs of urine content was apparent in
any of the PDGF-B null urinary bladders studied at this time point
[5].
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Fig. 1. Chimeric mice that lack PDGF in their
circulating cells provide a usejid model to test the
role of PDGF in the development of lesions of
atherosclerosis. Lethal irradiation of Apo E —I—
mice followed by replacement of their bone
marrow by fetal liver cells from embryonic
lethal mutations lacking the PDGF genes
creates chimeric animals with circulating cells
competely devoid of the targeted PDGF gene.
The different stages of lesion development can
______
then be compared in animals that received
40 transplants from embryos with the targeted
weeks disruption and animals that received transplants
from normal littermate control embryos.Lesion development
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Fig. 2. In mice deficient for PDGF-B, kidney glomendar tufts do not form
apparently due to an absence of mesangial cells. Kidneys from wild-type (A)
and mutant (B) E18 embryos were sectioned and stained with periodic
acid-Schiff's reagent. Note the lack of capillary tuft and the distended
capillary loop that fills the glomerular space in the section of the mutant
kidney (B).
PDGF-A knock-out phenotype
PDGF-A null mice were first found to develop until birth and
live for a few weeks postnatally, at which time they appeared
severely growth retarded. Closer analysis showed that these mice
invariably suffer from generalized lung emphysema, with resulting
atelectasis mixed with with hyperinflated regions [7]. The lung
emphysema and its cause will be discussed in more detail below.
Subsequent breeding and collection and genotyping of large
numbers of offspring at various embryonic ages reveals that there
is also loss of PDGF-A null embryos during early gestation [7].
From the analyses performed to date, it was concluded that there
is loss of approximately 50% of the PDGF-A null homozygotes
before ElO, but the cause of this loss and the mutant phenotype
at this early age are currently unknown. However, the expression
pattern of PDGF-A and -Ra is clearly consistent with early
embryonic functions for this ligand receptor pair. Both genes
appear transcribed in the preimplantation embryo [18, 19]. In
Xenopus eggs, there is also evidence for maternally-derived
PDGF-A mRNA [20]. Following implantation PDGF-A and -Rn
soon adopts an appositional expression pattern, and as time
passes, PDGF-A appears generally expressed in epithelial tissues
and PDGFRa in mesenchymal tissues [19, 21, 22]. It is likely that
the early embryonic loss of PDGF-A null homozygotes reflect this
expression pattern and the assumed epithelium-to-mesenchyme
signaling.
More intriguing is perhaps that 50% of the PDGF-A null
homozygotes apparently pass this early restriction point relatively
unaffected. The nature of the factors providing this variability in
PDGF-A null phenotypes needs further study. Genetic factors of
the embryo cannot be excluded since our previous analyses have
been performed on C57B1/6 x 129Sv hybrids. Backcrossing
programs to homogeneous genetic backgrounds are currently in
progress and are a prerequisite for addressing this question. Other
possible explanations for the PDGF-A null phenotype variablility
may include genetic factors of the mother, in turn affecting
PDGF-A dependent mother-embryo interactions. The most sim-
ple scenario would be PDGF-AA transport accross the placenta,
either from the mother to the embryo, to substitute embryonic
loss of PDGF-A, or from the embryo to the mother, affecting,
such as the maternal placenta or uterine function. Epigenetic
factors of the embryo and/or the mother have to be considered,
too.
The PDGF-A null embryos surviving beyond ElO appear
slightly growth retarded at E16-P2, after which point the growth
retardation becomes increasingly severe. From approximately two
weeks of age, the PDGF-A null homozygotes are invariably less
than 50% the size of heterozygote or wild-type littermates. The
nature of this dwarfness is intriguing. It was speculated that the
progressing emphysema leads to a chronic respiratory insuffi-
ciency, which in turn hampers general postnatal metabolism and
growth [7]. However, other explanations need to be considered as
well. For example, the prenatal growth retardation cannot be
secondary to a lung deficiency. During the last third of the mouse
embryonic development, PDGF-A and -Rn are strongly expressed
in an appositional manner. At E15, PDGF-A expression occurs in
most epithelia, irrespective of origin (ectodermal, endodermal or
mesodermal), as well as in muscle (skeletal, cardiac and smooth
muscle) and nervous tissue (Karlsson et al, unpublished data).
PDGFRn appears expressed in all mesenchymal cells, including
developing fibroblasts and SMC. It is possible that the widespread
expression of PDGF-A in the mid-to-late gestational mouse
embryo provides a trophic signal for the inesenchyme. In the
absence of PDGF-A, the population of mesenchymal cells may be
generally reduced in a nonspecific manner (in addition to the
specific and qualitative difference that occurs in the lung, as
further discussed below). Since epithelial growth and differentia-
tion is driven to a large extent by mesenchymal signals, the net
result of loss of PDGF-A may be a symmetrical growth retarda-
tion, as is the case in the PDGF null embryos surviving beyond
ElO.
Emphysema in PDGF-A null mice as a result of alveolar
myofibroblast deficiency
At three weeks of postnatal age, the PDGF-A null mice have
invariably developed a severe generalized lung emphysema (Fig.
4). Histologically, grossly enlarged distal air spaces were seen
without signs of subcompartmentalization by alveolar walls. As
expected, it was found that the emphysema had a developmental
origin; rather than occurring as a result of destruction of alveolar
walls, alveolar walls were never formed [7]. In the mouse,
alveogenesis normally starts around one week postnatally, and is
completed at three to four weeks of age. Before the onset of
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Fig. 3. Electron microscopy of mutant glomeruli suggest that without the mesangial cells, mechanical support for the glomerular basement membrane is
lacking. The podocytes and the glomerular basement membrane of the mutant PDGF-B E18 glomeruli appear normal, but the basement membrane with
attached podocytes appear tightly squeezed towards the parietal Bowman's epithelium. Magnification is 960x (A) and 3200x (B).
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putative alveolar SMC progenitor. Such cells were absent in the
mutant lung. However, many other sites of PDGFRcE expression,
both in the lung and in other tissues, remained unaffected in the
mutants. Based on these observations, it was proposed that the
alveolar SMC deficiency in PDGF-A null lungs reflects the failure
of a population of PDGFRa positive alveolar SMC progenitors to
develop during late gestation of the mouse [7]. It was also
proposed that the PDGFRa positive cells are turning on elastin
expression at the onset of alveogenesis. In the mature lung, both
PDGFRa and elastin mRNA expression is down-regulated in the
differentiated alveolar SMC, which are instead a-smooth muscle
actin positive. The nature of failure of the PDGFRa positive cells
at E18.5 or earlier, that is, whether it reflects lack of proliferation,
migration, survival or differentiation of the specific population of
PDGFRa positive cells, is a matter of current study. The devel-
oping lung epithelium, like other epithelia, is expressing PDGF-A,
and is therefore likely the critical source of ligand for the
PDGFRa positive cells.
Connective tissue cells and PDGF in development
Fig. 4. Alveolar septation fails to occur in PDGF-A null lungs. The mor-
phology of a wild-type (A) and PDGF-A null lung (B) at P19 is shown for
sections stained with Van Gieson elastin stain.
alveogenesis, the distal airspaces are refered to as prealveolar
saccules. These have a normal histology in PDGF-A null mice,
again emphasizing that the growth retardation of PDGF-A null
mice prior to one week of age, is not likely related to impairment
of lung function.
The mature alveolar septa contain alveolar smooth muscle cells
(also called contractile interstitial cells) embedded in deposits of
elastin. In the PDGF null lungs, the following defects associated
with the alveolar smooth muscle cells (SMC) were found. (i) At
three weeks of age, alpha smooth muscle actin positive cells were
absent in the mutant lungs, while in the normal lungs, such cells
were readily detected in alveolar septa. (ii) The three-week-old
mutant lung also displayed a considerable (>80%) reduction in
the content of extracellular elastin deposits. In particular, the
thick elastin fibres normally situated at the edge of the alveolar
septa were absent. In contrast, elastin deposits occurred normally
in mutants in blood vessel and bronchus walls in the lungs and in
blood vessel walls outside the lung. (iii) Elastin mRNA positive
cells with a histological localization correlating with that of
alveolar SMC or their immediate precursors were specifically
absent in the mutant lungs. In agreement with the distribution of
extracellular elastin deposits in the lung and elsewhere, such cells
were present at other locations in the mutant lungs (such as
vascular and bronchus walls) and at other sites outside the lung.
(iv) A population of PDGFRa positive cells was identified in the
normal E18.5 lung, which had the expected distribution of a
The analogy between the mesangial cells deficiency in PDGF-B
knock-outs and the alveolar SMC deficiency in PDGF-A knock-
outs is striking and may suggest a common (and ancient) role for
PDGFs in the development of certain subtypes of connective
tissue cells. In the cases of mesangial cells and alveolar SMC, their
absence leads to the failure of involution of an epithelial sheet,
consisting of podocytes in the kidney, and of pneumocytes in the
lung. In these cases involution creates a large active surface for
filtration and gaseous exchange, respectively. The contractile
properties of these connective tissue cells also suggest dynamic
functions. Mesangial cells have been suggested to regulate gb-
merular blood flow and primary urine production by way of
contracting the glomerular tuft [23].By contracting, alveolar SMC
have been suggested to influence alveolar capillary blood flow and
oxygenation [24].
The production of a higly specialized extracellular matrix
(mesangial matrix and elastin, respectively) appears to be a critical
property of mesangial cells and alveolar SMC. Involution of the
epithelial sheet is probably a direct consequence of extracellular
matrix production and, in the case of the glomerulus, appears to
be a consequence of focal attachment of the mesangial matrix to
the gbomerular basement membrane. Likewise, the localized
elatin deposition in the wall of the prealveolar saccules is likely
providing the mechanical driving force (elastic sphincters) leading
to compartmentalization of the prealveolar saccules into alveoli.
The latter finds support in the pathogenesis of emphysema. It is
generally assumed that in human emphysema results from the
degradation of alveolar septal elastin, either caused by an imbal-
ance between elastases and elastase inhibitors, as in a1-antitrypsin
deficiency, or as a result of increased local concentration of
elastases in the lung as occurs in conjunction with chronic
bronchitis in, for example, smokers. Thus, breakdown of septal
elastin leads to the same end result as failure of septal elastin
deposition (Fig. 5).
PDGF and the smooth muscle cell response to vascular injury
Although the role of PDGF in SMC and vascular development
is still not clear, several examples exist for a strong association of
PDGF-B and PDGFRf3 expression with vascular injury. In Figure
6, no PDGF-B is observed in a normal vessel (Fig. 6B) and only
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Fig. 6. PDGF-B and the PDGF 13-receptor are expressed at low levels in
normal vessels and up-regulated in developing lesions of atherosclerosis. A
normal non-human primate vessel (B) or early lesions in hypercholester-
olemic non-human primates (A and C) were stained for PDGF-B (A and
B) or the PDGF 13-receptor (C). PDGF-B staining is only observed in the
early lesion of atherosclerosis (A). Only weak staining for the PDGF
/3-receptor is observed in the underlying media of the early lesion of
atherosclerosis, but more intense staining is observed in the forming
intimal lesion (C).
Fig. 5. Comparison of the physiological process
of alveolar septation and pathological processes
involved in the development of emphysema. Lung
emphysema is defined as enlargment of the
airspaces distal to the terminal bronchioles [43].
It is believed to be a result of breakdown of
alveolar elastin by elastases released from
neutrophils or macrophages, when this enzyme
is not sufficiently inhibited by antiproteinase
(al-antitrypsin). This could happen either in
case of primaly ol-antitrypsin deficiency or,
more often, in smokers where csl-antitrypsin is
inhibited by oxidants in tobacco smoke 441• In
contrast, lung emphysema in PDGF-A mutants
results from the failure of alveolar septation, in
which process the formation of septal elastin
deposits by alveolar SMC is implicated.
Fig. 7. Expression of PDGF-B is increased surrounding foci of SMC that
appear to be migrating from the media into the intima. An intermediate
lesion from a hypercholesterolemic non-human primate was stained for
SMC a-actin and proliferating cell nuclear antigen (black nuclei), an
indicator of proliferation (A and B). Staining of an adjacent Section for
PDGF-B demonstrated increased expression (C) in areas surrounding the
foci of cells whose orientation is perpendicular to the medial SMC, some
of which appear to be proliferating (B).
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low levels of PDGFR/3 are observed in the media underlying the
early atherosclerotic lesion (Fig. 6C). However, significant expres-
sion of PDGF-B (Fig. 6A) and PDGFR13 (Fig. 6C) is observed in
early atherosclerotic lesions and at all stages of lesion develop-
ment [101. A critical phase in the development of lesions of
atherosclerosis is the migration of SMC from the media into the lymphocytes. Examination of these cells at high power demon-
intima [25]. As shown in Figure 7, foci of SMC whose orientation strates that some of these cells that are stained with an antibody
is perpendicular to that of cells in the media are readily identified
in lesions that appear to be in the early phases of SMC migration
into the intimal space primarily occupied by macrophages and
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to SMC a actin (Fig. 7B), also have black nuclei indicative of cells
undergoing proliferation (stained with an antibody to proliferat-
ing cell nuclear antigen). In areas immediately surrounding the
SMC that appear to be both migrating and proliferating is strong
staining for PDGF-B (Fig. 7C), primarily in macrophages (data
not shown) [101. Thus, expression of PDGF-B and PDGFRf3 is
associated with the infiltration and accumulation of SMC, the cells
responsible for the subsequent accumulation of extracellular
matrix that further expands lesion volume [26].
More direct evidence for a role for PDGF in SMC accumula-
tion comes from antibody inhibition studies in the rat balloon
injury model of the rat carotid artery. In this model, Reidy and his
colleagues have shown that the initial mural thrombi that form
following de-endotheialization are critical to the subsequent
intimal SMC accumulation, as rats made thrombocytopenic show
a marked decrease in neointima formed over the following two
weeks [271. In similar experiments in which a neutralizing poly-
clonal anti-PDGF antibody was admininistered one day prior to
and daily following balloon injury in an athymic nude rat, the
neutralizing PDGF antibody reduced neointimal accumulation at
eight days by approximately 40% [131. Evaluation of the prolifer-
ative indices of the SMC in these same animals showed no
difference between the anti-PDGF-treated animals and controls.
The data imply that within the time frame examined (between
days 7 and 8 following balloon injury) and for the dose of
anti-PDGF administered, the decrease in intimal area is primarily
due to interference with PDGF-induced migration of medial SMC
into the intima. In the same model, SMC are first detectable in the
intima three days after injury with a few cells covering 0.2% of the
intimal surface. However, four days after injury, the proportion of
the intima covered by SMC is 11%, a 52-fold increase that is too
large to be caused by proliferation. Administration of anti-PDGF
antibody reduced migration measured on day 4 by 79% [281. Thus,
a clear in vivo role for PDGF has been established in a model of
vascular injury, one in which the ability of PDGF to stimulate
smooth muscle cell migration into the intima is particularly
prominent.
PDGF in glomerular disease and pulmonary fibrosis
A number of studies of experimental glomerulonephritis have
also demonstrated an association between glomerular expression
of PDGF and PDGFR and mesangial cell proliferation [29 —321.
Other studies have revealed an inhibitory effect of infused PDGF
antibodies on mesangial cell proliferation following the induction
of experimantal glomerulonephritis in rats [32]. Thus, the same
molecules (PDGF-B and -Rp) that appear critically involved in
mesangial cell ontogeny also appear to play a role in mesangial
cell pathological reaction in conjunction with certain types of
glomerulonephritis.
Expression and secretion of PDGF-A and -B have also been
observed from lung macrophages in conjunction with idiopathic
pulmonary fibrosis (IPF) or pulmonary fibrosis of other etiologies
[33—35]. However, the origin of the reactive connective tissue cells
in 1FF and any possible connection to alveolar SMC remains to be
established. Thus, in both of the organs characterized by severe
abnormalities in the PDGF null mutants, the kidney and the lung,
increased expression of PDGF is also observed in fibroprolifera-
tive pathology.
Infusion of PDGF into injured vessels and glomeruli:
Implications for cell and matrix accumulation
To examine the ability of PDGF-BB to stimulate SMC migra-
tion and proliferation in the injured rat carotid artery, PDGF was
continuously infused for seven days [36]. Rats were continously
infused with vehicle or PDGF with or without gentle endothelial
injury of the rat carotid artery, together with continuous intraper-
itoneal infusion of tritiated thymidine for seven days. Intimal
lesion area in rats infused with PDGF was 15-fold greater than
that observed in vehicle-treated animals following endothelial
injury, but no response was observed without endothelial injury. A
21-fold increase in the number of unlabeled cells was observed in
the neointima of PDGF-treated animals as well as a fourfold
increase in thymidine incorporation in medial SMC. Thus, disrup-
tion of the endothelial cell lining of the vessel and the matrix
surrounding SMC was required for a response to infused PDGF,
and the principal effect of PDGF on intimal lesion formation was
stimulation of medial smooth muscle migration into the intima.
Interestingly, it has recently been reported that differential ex-
pression of a1 type VIII collagen is observed in the carotid artery
following infusion of PDGF coincident with SMC migration into
the intima, and thus it may play a role in mediating this response
to injury [37].
Infusion studies in the rat glomerulus also demonstrate mesan-
gial cell accumulation and up-regulation of extracellular matrix
[38]. PDGF, like TGF-J3, has been shown to be a potent stimulant
of matrix deposition in the glomerulus following anti-Thy 1 injury,
and treatment with antibodies to PDGF inhibit matrix accumula-
tion [32]. Specific increases in expression of type IV collagen,
laminin, and fibronectin were associated with animals that were
perfused with PDGF following a subnephritogenic dose of anti-
Thy 1.1 antibody (an antigen specific to mesangial cells). Glomer-
ular cell proliferation was highest on day 2 with approximately
14% of the cells positive for PCNA. This decreased to 7% on days
4 and 7, despite continued infusion of PDGF. Increases in
collagen were evident after four days while changes in laminin and
fibronection were observed even two days after starting the
infusion.
Interestingly, it has been shown that both mesangial cells [38]
and SMC [39] on polymerized collagen fail to proliferate in
response to PDGF in vitro. It is possible that the lack of response
of the normal vessel and the decreased response of the injured
glomerulus to PDGF at later time points reflects a non-permissive
state induced by the extracellular matrix surrounding the cells. In
such a model, the normal matrix surrounding the cells, unless
disrupted, would prevent a response to locally released PDGF.
Further, PDGF stimulation of extracellular matrix accumulation
following injury could be an autoregulatory mechanism to limit
proliferation.
PDGF regulation of connective tissue cells
Thus, in both the knock-out models and pathologic states
PDGF appears to be critical for the migration and expansion of
connective tissues cells and stimulation of the production of highly
specialized extracellular matrix. Connective tissue cells appear in
many ways unique in their ability to reversibly change their
phenotype in response to activation, referred to as a switch to a
synthetic phenotype for SMC [40] and as "myofibroblasts" in
wound healing [41]. In tissue morphogenesis and wound repair,
1368 Betsholtz and Raines: PDGF and connective tissue
connective tissue cells must attach to new matrix molecules and
migrate. Modeling of the different matrices in wound healing (the
normal dermis, early wound provisional matrix, and late granula-
tion tissue) has demonstrated that the different matrices dramat-
ically alter the fibroblast response to PDGF, specifically the
expression of integrins that regulate the cell's interaction with the
matrix [42]. Thus, PDGF, with its multipotential activities, and
extracellular matrix, also regulated by PDGF, have the ability to
coordinately alter connective tissue cell phenotype. Understand-
ing this interplay is critical to defining the regulatory role of
PDGF in tissue morphogenesis and pathologic processes such as
atherosclerosis.
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